As of September 30, 2009, MZEI has a working capital deficiency of $3,265,784, compared to a working capital deficiency of $3,394,071 at December 31, 2008. The stockholders' deficit at September 30, 2009 was $3,479,870 compared to $3,615,326 at December 31, 2008. MZEI reported no revenues due to being a development stage company. The only source of financing to date has been the sporadic sale of common stock. During the nine months ended September 30, 2009, MZEI generated cash of $768,000 through common stock sales at prices ranging from $0.02 to $0.03 per share. During October and November 2009, an additional $232,100 was raised through the sale of common stock at $0.06 per share.
Additional financing is necessary for this MZEI to sustain operations. If there is no additional financing, MZEI might have to curtail or discontinue operations, or seek protection under the bankruptcy laws.
As of today November 25, 2009, MZEI is one of the top advancers with at 19%. This stock is hot and continues to be on the rise.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
Medizone International, Inc., is a research and development company engaged in developing its AsepticSure(TM) technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. Current trials are now being expanded to include a hospital mock-up to be followed by hospital beta testing. Initial sales are targeted to commence early in 2010.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
